Jeffrey Hobbs graduated from the London School of Economics. Following a career in the healthcare business of Guinness plc, he led the establishment of the UK business of Ferring Pharmaceuticals and is currently Vice Chairman and Executive Director of the Ferring Group. In addition, Jeffrey Hobbs is a Director of the C&P Group.
Dean Slagel has 30 years of biopharmaceutical industry and venture investing experience and an MBA from ENPC Business School, Paris. Following 10 years with Ferring in global operations and business development management, he led Esperante since 2004, building an investment portfolio across North America, Europe and Israel with 3 successful exits and 2 successful public listings.
Erik Schropp, a Dutch citizen is CEO of C&P Investors, a Director of Draupnir Holding BV and of PolyPeptide Group. Previously, Mr. Schropp held various senior finance functions in the pharmaceutical industry and is currently Board Director of various privately held companies in life sciences and gene therapy in addition to Esperante. He holds a Master’s degree in Economics & Tax from the Erasmus University Rotterdam, The Netherlands.
Following a successful 30 year career in senior national and international marketing roles at Ferring Pharmaceuticals, most recently as General Manager of Ferring UK, Sean Davis is currently Director of Commercial Operations of the C&P Group and a Director of its Draupnir Group pharmaceuticals subsidiary in addition to Esperante.
Sandy Primrose graduated from the University of Strathclyde, Scotland and the University of California at Davis. He has spent over 40 years in senior management roles in the global pharmaceutical, diagnostic and biotechnology industries including Searle/Monsanto and Amersham Diagnostics. He is currently Chairman of AMLo Biosciences and Newcells Biotech and was previously Chairman of Arquer Diagnostics and Non-Executive Director of Mologic.
Andrew graduated from Imperial College London with a Bachelors in Biological Sciences and holds a Master of Science in Immunology and Immunotherapy from the University of Birmingham. Following three years as an analyst for a biotech investment fund and sustainable finance data provider, Andrew is currently the investment analyst for Esperante.